Vanguard Group Inc. Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Vanguard slightly raised its stake to 9,075,153 shares (about 8.63% of Regeneron), valuing its holding at roughly $7.0 billion, underscoring heavy institutional ownership.
• FDA approves Otarmeni, Regeneron’s gene therapy for inherited deafness, and the company said it will provide the therapy free to eligible U.S. patients while also securing three years of tariff relief—offset by a separate drug‑pricing deal that could compress margins.
• Analysts are mostly bullish, with several firms raising price targets (e.g., Guggenheim to $975, TD Cowen to $960) and a consensus rating of “Moderate Buy,” while Regeneron also raised its quarterly dividend to $0.94 per share.

Vanguard Group Inc. raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 0.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,075,153 shares of the biopharmaceutical company's stock after acquiring an additional 26,884 shares during the period. Vanguard Group Inc. owned about 8.63% of Regeneron Pharmaceuticals worth $7,004,838,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the business. WPG Advisers LLC boosted its stake in shares of Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 25 shares in the last quarter. Salomon & Ludwin LLC bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $27,000. Board of the Pension Protection Fund purchased a new position in Regeneron Pharmaceuticals in the 4th quarter worth $31,000. Caitlin John LLC bought a new stake in Regeneron Pharmaceuticals in the third quarter worth $34,000. Finally, FNY Investment Advisers LLC purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at about $38,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the company's stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the transaction, the director directly owned 17,803 shares in the company, valued at approximately $13,860,169.59. This represents a 0.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Huda Y. Zoghbi sold 1,638 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the sale, the director directly owned 1,703 shares in the company, valued at $1,330,604.99. The trade was a 49.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,774 shares of company stock worth $2,942,738 over the last quarter. 7.02% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

REGN has been the topic of a number of recent research reports. JPMorgan Chase & Co. raised their price objective on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an "overweight" rating in a research note on Monday, February 2nd. Guggenheim boosted their target price on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the company a "buy" rating in a research note on Monday, February 9th. Sanford C. Bernstein dropped their target price on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an "outperform" rating for the company in a report on Wednesday, April 8th. Piper Sandler started coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 31st. They issued an "overweight" rating and a $875.00 price target on the stock. Finally, TD Cowen boosted their price objective on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a "buy" rating in a research report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $825.35.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: FDA approves Otarmeni (lunsotogene parvec-cwha), the first gene therapy to restore hearing — pivotal CHORD data showed ~80% met the primary endpoint and 42% achieved normal hearing on longer follow‑up, marking a breakthrough product and validating Regeneron’s genetic‑medicine efforts. Read More.
• Positive Sentiment: Analyst support: TD Cowen raised its price target to $960 (buy) and Cantor Fitzgerald reaffirmed an overweight rating with an $800 target — institutional upgrades can support upside as investors re‑rate growth prospects. Read More.
• Positive Sentiment: Regeneron reportedly secured tariff relief from the U.S. government for three years as part of the deal, which mitigates some cost headwinds and is a near‑term financial benefit. Read More.
• Neutral Sentiment: Regeneron will provide Otarmeni for free to eligible U.S. patients — a major access/PR move that increases uptake and public goodwill but has ambiguous near‑term revenue implications. Read More.
• Neutral Sentiment: Q1 preview / estimates: Research outlets (Zacks) are parsing Wall Street’s revenue and key‑metric estimates ahead of quarterly reporting — results will be important for near‑term stock direction. Read More.
• Neutral Sentiment: CEO Leonard Schleifer said Regeneron will provide Otarmeni for free in the U.S. but hasn’t decided on overseas pricing — international price strategy remains uncertain and will affect global revenue potential. Read More.
• Negative Sentiment: Drug‑pricing deal: Regeneron agreed to offer some prescriptions at “most‑favored‑nation” (MFN) prices and to lower U.S. drug costs under the administration deal — investors worry this could compress margins and reduce pricing power across the portfolio. Read More.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $751.57 on Monday. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. The company has a 50-day moving average price of $762.84 and a 200-day moving average price of $733.31. The company has a market cap of $79.46 billion, a price-to-earnings ratio of 18.08, a price-to-earnings-growth ratio of 1.67 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company had revenue of $3.88 billion for the quarter, compared to analysts' expectations of $3.76 billion. During the same period last year, the firm earned $12.07 earnings per share. Regeneron Pharmaceuticals's quarterly revenue was up 2.5% on a year-over-year basis. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.2 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. This is a boost from Regeneron Pharmaceuticals's previous quarterly dividend of $0.88. The ex-dividend date of this dividend was Friday, February 20th. Regeneron Pharmaceuticals's payout ratio is presently 9.05%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.